Optrin

Optrin

Ophthalmology An agent–lutetium texaphyrin–Lu-Tex used in photodynamic therapy of eye diseases–eg, age-related macular degeneration. See Age-related macular degeneration.
References in periodicals archive ?
orbignyi, the peptide name Optrin was isolated that causes vasoconstriction and which sequence of amino acids is His-Gly-Gly-Tyr-Lys- Pro-Thr-Asp-Lys, aligned by creatine kinase residues in 97-105, without any similarity with another bioactive peptide (Table 2) [26].
As announced in October 2001, the company regained the worldwide rights to develop and market Optrin from Alcon.
Pharmacyclics will continue to develop Optrin based on its analysis of preliminary data from a 75-patient Phase II dose-ranging clinical trial recently completed by Alcon.
Pharmacyclics and Alcon entered into an evaluation and license agreement in December 1997 for the commercialization of Optrin for ophthalmology indications, including ARMD.
All patients received a single intravenous injection of Optrin, followed by light delivered to the retina.
0 million milestone from Alcon related to the development of Optrin.
Optrin could be shown to be present in the CNV and, in selected patients, resulted in complete or partial closure of diseased vessels following activation with light.
Optrin is one of a group of drugs based on Pharmacyclics' patented synthetic molecules called texaphyrins.
Alcon has been conducting preclinical and clinical development of Optrin for the photodynamic therapy (PDT) of patients with age-related macular degeneration (ARMD), the leading cause of blindness in the United States.
As we move further along in our clinical studies with Optrin, we are increasingly optimistic about its potential in treating ARMD," said Gerald D.
Under the terms of the agreement, Alcon conducts and bears all costs for worldwide development and drug registration for ophthalmology indications of Optrin.
Based on these favorable results, OPTRIN now becomes Pharmacyclics' fourth product in advanced clinical testing.